Invivyd (NASDAQ:IVVD - Get Free Report) is set to release its earnings data before the market opens on Thursday, November 14th. Analysts expect Invivyd to post earnings of ($0.32) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.
Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The firm had revenue of $2.26 million during the quarter, compared to analysts' expectations of $4.91 million. On average, analysts expect Invivyd to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Invivyd Stock Performance
NASDAQ IVVD traded down $0.04 during trading hours on Thursday, reaching $1.00. The stock had a trading volume of 370,072 shares, compared to its average volume of 629,856. Invivyd has a 52-week low of $0.81 and a 52-week high of $5.20. The stock has a fifty day moving average of $0.99 and a 200 day moving average of $1.35. The stock has a market cap of $119.44 million, a P/E ratio of -0.56 and a beta of 0.65.
Analyst Ratings Changes
IVVD has been the subject of several recent research reports. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Invivyd in a research note on Tuesday, October 29th.
Check Out Our Latest Analysis on IVVD
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Further Reading
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
